Resalis Therapeutics
ID: 12432780Resalis Therapeutics is developing first-in-class anti-miR compounds to address high unmet medical needs in liver diseases, metabolic disorders, and cancer using a multi-pathway approach.
1
Funding Rounds
$11.0m
Money raised
Recent Funding Rounds
Overview
Resalis Therapeutics is developing first-in-class anti-miR compounds to address high unmet medical needs in liver diseases, metabolic disorders, and cancer using a multi-pathway approach.
- Website:
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding series
Funding Series Analysis
The company Resalis Therapeutics has raised a total of $11m in funding over 1 rounds.
Key Insights:
- Resalis Therapeutics February 2023 Seed Funding Round: $11m
Industries
Resalis Therapeutics is active in the following industries: